JP2012067115A5 - - Google Patents

Download PDF

Info

Publication number
JP2012067115A5
JP2012067115A5 JP2011243450A JP2011243450A JP2012067115A5 JP 2012067115 A5 JP2012067115 A5 JP 2012067115A5 JP 2011243450 A JP2011243450 A JP 2011243450A JP 2011243450 A JP2011243450 A JP 2011243450A JP 2012067115 A5 JP2012067115 A5 JP 2012067115A5
Authority
JP
Japan
Prior art keywords
dosage form
oral dosage
solid oral
blend
rate controlling
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011243450A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012067115A (ja
JP5412491B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2012067115A publication Critical patent/JP2012067115A/ja
Publication of JP2012067115A5 publication Critical patent/JP2012067115A5/ja
Application granted granted Critical
Publication of JP5412491B2 publication Critical patent/JP5412491B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2011243450A 1999-02-22 2011-11-07 促進剤を含む固体経口剤形 Expired - Fee Related JP5412491B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12104899P 1999-02-22 1999-02-22
US60/121,048 1999-02-22

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2000600624A Division JP2002537321A (ja) 1999-02-22 2000-02-22 促進剤を含む固体経口剤形

Publications (3)

Publication Number Publication Date
JP2012067115A JP2012067115A (ja) 2012-04-05
JP2012067115A5 true JP2012067115A5 (enExample) 2012-09-20
JP5412491B2 JP5412491B2 (ja) 2014-02-12

Family

ID=22394170

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2000600624A Pending JP2002537321A (ja) 1999-02-22 2000-02-22 促進剤を含む固体経口剤形
JP2011243450A Expired - Fee Related JP5412491B2 (ja) 1999-02-22 2011-11-07 促進剤を含む固体経口剤形

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2000600624A Pending JP2002537321A (ja) 1999-02-22 2000-02-22 促進剤を含む固体経口剤形

Country Status (8)

Country Link
EP (1) EP1154761B1 (enExample)
JP (2) JP2002537321A (enExample)
AT (1) ATE386508T1 (enExample)
AU (1) AU2681300A (enExample)
CA (1) CA2363123C (enExample)
DE (1) DE60038097T2 (enExample)
ES (1) ES2301477T3 (enExample)
WO (1) WO2000050012A1 (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000029049A1 (en) 1998-11-13 2000-05-25 Elan Pharma International Limited Drug delivery systems and methods
US7084279B1 (en) 1999-02-11 2006-08-01 Emisphere Technologies Inc. Oxadiazole compounds and compositions for delivering active agents
US7658938B2 (en) 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
JP2007016034A (ja) * 2000-12-26 2007-01-25 Kirin Brewery Co Ltd 吸収促進剤
EP1390048A2 (en) * 2001-02-16 2004-02-25 Shimizu Pharmaceutical Co., Ltd. Oral formulations containing mucopolysaccharide for small intestine delivery and their use in the treatment circulatory disorders
EP1390383B1 (en) 2001-05-11 2012-02-29 Isis Pharmaceuticals, Inc. Antisense permeation enhancers
WO2006097793A2 (en) 2004-04-15 2006-09-21 Chiasma, Ltd. Compositions capable of facilitating penetration across a biological barrier
CN103223160B (zh) * 2004-07-19 2015-02-18 比奥孔有限公司 胰岛素-低聚物共轭物,制剂及其用途
AU2014200247B2 (en) * 2004-07-19 2015-05-14 Biocon Limited Insulin-oligomer conjugates, formulations and uses thereof
US20060078623A1 (en) * 2004-08-13 2006-04-13 Emisphere Technologies, Inc. Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent
JP4759289B2 (ja) * 2005-03-02 2011-08-31 国立大学法人北海道大学 カルシウム吸収促進組成物およびその利用
WO2007117706A2 (en) 2006-04-07 2007-10-18 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
EP2040731A4 (en) * 2006-06-09 2010-05-19 Merrion Res Iii Ltd SOLID DOSAGE FORM FOR ORAL ADMINISTRATION CONTAINING AN ACTIVATOR
CL2007002618A1 (es) * 2006-09-12 2008-03-14 Glaxo Group Ltd Composicion farmaceutica de liberacion modificada oral que comprende una pluralidad de mini-comprimidos con un diametro menor que 5 mm y comprendiendo un inhibidor del factor xa dentro de una matriz de uno o mas polimeros; procedimiento de preparacio
US9241908B2 (en) * 2007-10-16 2016-01-26 Biocon Limited Orally administrable solid pharmaceutical composition and a process thereof
CN103536923A (zh) * 2007-11-05 2014-01-29 阿拉维制药公司 用于口服给药极性药剂的提高生物利用度的制剂
CN102046192B (zh) 2008-05-07 2014-11-19 默里昂研究Ⅲ有限公司 GnRH相关化合物的组合物及制备方法
ES3058497T3 (en) 2008-09-17 2026-03-11 Amryt Endo Inc Pharmaceutical compositions comprising polypeptides and related methods of delivery
GB0904942D0 (en) * 2009-03-23 2009-05-06 Ntnu Technology Transfer As Composition
DK2459176T3 (en) 2009-07-31 2017-12-04 Gruenenthal Gmbh Crystallization process and bioavailability
US20160016982A1 (en) 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
WO2011084618A2 (en) 2009-12-16 2011-07-14 Nod Pharmaceuticals, Inc. Compositions and methods for oral drug delivery
US20110182985A1 (en) * 2010-01-28 2011-07-28 Coughlan David C Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
WO2011120033A1 (en) * 2010-03-26 2011-09-29 Merrion Research Iii Limited Pharmaceutical compositions of selective factor xa inhibitors for oral administration
US9340565B2 (en) 2010-11-24 2016-05-17 Thar Pharmaceuticals, Inc. Crystalline forms
EP2651395A4 (en) * 2010-12-15 2014-05-07 Merrion Res Iii Ltd PHARMACEUTICAL COMPOSITIONS OF SELECTIVE FACTOR XA INHIBITORS FOR ORAL ADMINISTRATION
PL2651398T3 (pl) 2010-12-16 2018-05-30 Novo Nordisk A/S Stałe kompozycje zawierające agonistę GLP-1 i sól kwasu N-(8-(2-hydroksybenzoilo)amino)kaprylowego
WO2012094598A2 (en) * 2011-01-07 2012-07-12 Merrion Research Iii Limited Pharmaceutical compositions of iron for oral administration
DK2696687T3 (en) 2011-04-12 2017-02-06 Novo Nordisk As Double-acylated GLP-1 derivatives
HUE042757T2 (hu) 2012-03-22 2019-07-29 Novo Nordisk As Szállító szert tartalmazó készítmények és elõállításuk
PL3542790T3 (pl) 2012-03-22 2024-02-26 Novo Nordisk A/S Kompozycje zawierające substancję dostarczającą i ich przygotowanie
EP4324475A1 (en) 2012-03-22 2024-02-21 Novo Nordisk A/S Compositions of glp-1 peptides and preparation thereof
JP6517690B2 (ja) 2012-06-20 2019-05-22 ノヴォ ノルディスク アー/エス ペプチド及び送達剤を含む錠剤製剤
KR20210086717A (ko) 2013-05-02 2021-07-08 노보 노르디스크 에이/에스 Glp-1 화합물의 경구 투여
US10265384B2 (en) 2015-01-29 2019-04-23 Novo Nordisk A/S Tablets comprising GLP-1 agonist and enteric coating
PL3253401T3 (pl) 2015-02-03 2025-08-04 Amryt Endo, Inc. Leczenie akromegalii oktreotydem doustnym
EP3280447B1 (en) * 2015-04-08 2019-02-27 Torrent Pharmaceuticals Limited Pharmaceutical formulations
GB201515387D0 (en) 2015-08-28 2015-10-14 Amazentis Sa Compositions
CN108699126B (zh) 2016-03-03 2022-12-06 诺和诺德股份有限公司 Glp-1衍生物及其用途
US10195218B2 (en) 2016-05-31 2019-02-05 Grunenthal Gmbh Crystallization method and bioavailability
JP2020527159A (ja) 2017-07-19 2020-09-03 ノヴォ ノルディスク アー/エス Egf(a)類似体、その製造、製剤および使用
WO2019149880A1 (en) 2018-02-02 2019-08-08 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant
US11141457B1 (en) 2020-12-28 2021-10-12 Amryt Endo, Inc. Oral octreotide therapy and contraceptive methods
JPWO2024143501A1 (enExample) * 2022-12-28 2024-07-04

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB953626A (en) * 1961-04-25 1964-03-25 Meito Sangyo Kk Enteric-coated tablets of dextran sulphate ester and method of preparation thereof
US4525339A (en) * 1982-10-15 1985-06-25 Hoffmann-La Roche Inc. Enteric coated oral dosage form
JPS5973600A (ja) * 1982-10-19 1984-04-25 Okayasu Shoten:Kk 排卵誘発剤
DE3331009A1 (de) * 1983-08-27 1985-03-14 Basf Ag, 6700 Ludwigshafen Verfahren zur erhoehung der enteralen resorbierbarkeit von heparin bzw. heparinoiden sowie das so erhaeltliche heparin- bzw. heparinoidpraeparat
ZA898331B (en) * 1988-11-22 1990-07-25 Hoffmann La Roche Pharmaceutical compositions
JPH03275633A (ja) * 1990-03-23 1991-12-06 Teikoku Seiyaku Co Ltd 生理活性ポリペプチドの吸収促進剤
JPH04149126A (ja) 1990-10-09 1992-05-22 Mitsubishi Kasei Corp 経粘膜投与用医薬組成物
IT1245761B (it) * 1991-01-30 1994-10-14 Alfa Wassermann Spa Formulazioni farmaceutiche contenenti glicosaminoglicani assorbibili per via orale.
CA2070061C (en) * 1991-06-07 2004-02-10 Shigeyuki Takama Physiologically active polypeptide-containing pharmaceutical composition
AU661080B2 (en) * 1991-11-22 1995-07-13 Warner Chilcott Company, Llc Risedronate delayed-release compositions
SE501389C2 (sv) * 1992-04-24 1995-01-30 Leiras Oy Farmaceutiskt preparat och förfarande för dess framställning
RU2068689C1 (ru) * 1992-09-24 1996-11-10 Товарищество с ограниченной ответственностью "Лекрон" Способ получения таблеток парацетамола
CA2148465C (en) * 1992-11-06 1999-11-02 Minenobu Okayama Oral pharmaceutical preparation releasable in the lower digestive tract
JPH06192107A (ja) 1992-12-25 1994-07-12 Sanwa Kagaku Kenkyusho Co Ltd グリチルリチン経口剤
GB9516268D0 (en) * 1995-08-08 1995-10-11 Danbiosyst Uk Compositiion for enhanced uptake of polar drugs from the colon
GB9614235D0 (en) * 1996-07-06 1996-09-04 Danbiosyst Uk Composition for enhanced uptake of polar drugs from mucosal surfaces

Similar Documents

Publication Publication Date Title
JP2013519632A5 (enExample)
JP2020094064A (ja) イルベサルタンとアムロジピンまたはその塩を含有する医薬組成物
JP2014501784A5 (enExample)
JP2015038135A5 (enExample)
JP2010505902A5 (enExample)
JP2009530398A5 (enExample)
CN1921840A (zh) 多层片剂
TWI700100B (zh) 用於口服投藥之包含依澤替米貝(ezetimibe)及羅舒伐他汀(rosuvastatin)的複合調配物及其製備方法
JP2015510916A5 (enExample)
JP2014503593A5 (enExample)
JP2010527347A5 (enExample)
JP2015521191A5 (enExample)
JP2013508289A5 (enExample)
JPWO2019151405A1 (ja) 錠剤及びその製造方法
JP2015522603A5 (enExample)
WO2010001413A3 (en) Sustained release pharmaceutical compositions comprising quetiapine
JP2011500811A5 (enExample)
JP2013545802A5 (enExample)
JP2010500284A5 (enExample)
JP2009502777A5 (enExample)
WO2005065664A8 (en) Pharmaceutical compositions comprising a proton pump inhibitor and a prokinetic agent
CA2648538A1 (en) Oral rapid release pharmaceutical formulation for pyridylmethylsulfinyl-benzimidazoles
US10258577B2 (en) Multilayer solid pharmaceutical dosage forms
JP2016527237A5 (enExample)
EP3397249B1 (en) Enteric coated oral pharmaceutical preparation comprising dimethyl fumarate